Logo XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. inflammatory condition
Show results for
Products
Services
Applications

Companies

News
Articles
Books
Downloads

Refine by
Date

  • Older

Inflammatory Condition Articles & Analysis

35 news found

Protheragen-ING Offers a Full Range of Nonsteroidal Anti-inflammatory APIs, Including Celecoxib and Crisaborole

Protheragen-ING Offers a Full Range of Nonsteroidal Anti-inflammatory APIs, Including Celecoxib and Crisaborole

To address this need, Protheragen-ING continues to prove itself as a top supplier of nonsteroidal anti-inflammatory APIs (NSAIDs), a class of anti-inflammatory APIs. These widely used compounds are helpful to manage various inflammatory conditions such as arthritis, musculoskeletal injuries, toothaches, menstrual pain and ...

ByProtheragen-ING


Dual Benefits of Compound 17B For Pulmonary Arterial Hypertension

Dual Benefits of Compound 17B For Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a progressive, life-threatening condition characterized by increased pulmonary arterial pressure, vascular remodeling, and persistent inflammation. ...

BySCIREQ - an emka TECHNOLOGIES Company


Treating Acute Inflammatory Lung Disease: The Promise of Trimannose-Coupled Antimir-21

Treating Acute Inflammatory Lung Disease: The Promise of Trimannose-Coupled Antimir-21

Recent advances in the fight against severe acute inflammatory lung diseases, including COVID-19, have revealed a promising new approach to treating pulmonary hyperinflammation and long-term lung damage such as fibrosis. A groundbreaking study has developed a first-in-class, carbohydrate-coupled inhibitor of microRNA-21 (RCS-21), which shows significant potential as a therapeutic agent. This ...

BySCIREQ - an emka TECHNOLOGIES Company


LEAP-2 detection with Bertin Bioregeant ELISA kit

LEAP-2 detection with Bertin Bioregeant ELISA kit

In addition, LEAP-2 helps regulate inflammatory responses and maintain the balance of the intestinal microbiota, thus promoting overall gastrointestinal health. Understanding the function and regulation of LEAP-2 is crucial for developing new therapeutic strategies against infectious diseases, inflammatory conditions and gastrointestinal ...

ByBertin Technologies


Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a preclinical proof-of-concept study

Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a preclinical proof-of-concept study

Gesynta Pharma AB today announces the decision to advance the development of its clinical-stage drug candidate GS-248 in endometriosis - a chronic inflammatory condition affecting approximately 10 percent of all women of reproductive age. ...

ByGesynta Pharma AB


INOVIQ carving itself healthy share of multi-billion dollar medical diagnostics market

INOVIQ carving itself healthy share of multi-billion dollar medical diagnostics market

“Our current focus is cancer, but there’s other diseases where our EXO-NET technology applies, including neurodegenerative diseases, inflammatory diseases and cardio-metabolic conditions,” Dr Hinch said. ...

ByINOVIQ Ltd


AOBiome Therapeutics Announces Appointment of Dr. Judith Ng Cashin as Chief Medical Officer

AOBiome Therapeutics Announces Appointment of Dr. Judith Ng Cashin as Chief Medical Officer

("AOBiome"), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that Dr. ...

ByAOBiome Therapeutic, LLC


Immune-Onc Therapeutics Receives China Investigational New Drug (IND) Approval for the Phase 1 Study of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Solid Tumors

Immune-Onc Therapeutics Receives China Investigational New Drug (IND) Approval for the Phase 1 Study of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Solid Tumors

Ex vivo studies show that treatment with IO-108 produces pro-inflammatory activity and an enhanced antigen-presenting cell (APC) phenotype to multiple stimuli, including T cell activators, and STING and TLR agonists. As a single agent, IO-108 reverts the anti-inflammatory myeloid cell phenotype caused by “tumor conditioning” to ...

ByImmune-Onc Therapeutics, Inc.


Tetra Bio-Pharma Announces Licensing Agreement with True North for Patented CBD Technology

Tetra Bio-Pharma Announces Licensing Agreement with True North for Patented CBD Technology

They bring a combined experience of over 100 years in research and clinical care of people dealing with chronic pain and inflammatory conditions. Panag's development pipeline of pain relief products include topical, oral, and ocular delivery solutions for challenging molecules. ...

ByTetra Bio-Pharma


Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation

Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation

“We believe that CAR-Tregs are the next frontier of cell therapy and represent a potentially transformational approach to solid organ transplantation as well as to many challenging autoimmune and inflammatory conditions. The STEADFAST Phase 1/2 study is an important milestone for genomic medicine that we anticipate will yield insights regarding CAR-Treg ...

BySangamo Therapeutics


Preventing Wound Infections and Complications at Urgent Care

Preventing Wound Infections and Complications at Urgent Care

Patients at Higher Risk of Wound Infections Some urgent care patients may have underlying conditions that could increase their risk of wound infections either due to the condition itself or the drugs used to treat it. ...

ByKitoTech Medical, Inc.


AOBiome’s B244 demonstrated positive results from its Phase 2b trial for both Pruritus (Itch) and Appearance of Atopic Dermatitis (Eczema)

AOBiome’s B244 demonstrated positive results from its Phase 2b trial for both Pruritus (Itch) and Appearance of Atopic Dermatitis (Eczema)

AOBiome Therapeutics, a clinical stage biotechnology company focused on transforming human health by developing topical biologic therapies for systemic inflammatory conditions, announced positive pivotal Phase 2b results from its trial evaluating B244 in both pruritus (itch) and appearance of atopic dermatitis (eczema). ...

ByAOBiome Therapeutic, LLC


Suono Bio, Inc. Announces Formulation-Agnostic Platform for the Delivery of RNA Therapeutics

Suono Bio, Inc. Announces Formulation-Agnostic Platform for the Delivery of RNA Therapeutics

In addition to previously demonstrating the preclinical use of siRNAs for treating inflammatory conditions, this latest publication demonstrates the ability to knockdown endogenous genes, including Ctnnb1, the gene encoding for beta-catenin, which plays a role in tumorigenesis in colorectal cancers, for example. ...

BySuono Bio


Neurent Medical Receives FDA Clearance for NEUROMARK, a Novel Multi-Point Nerve Disruption Treatment for Chronic Rhinitis

Neurent Medical Receives FDA Clearance for NEUROMARK, a Novel Multi-Point Nerve Disruption Treatment for Chronic Rhinitis

GALWAY, Ireland–Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced Food and Drug Administration (FDA) clearance of its proprietary NEUROMARK™ Rhinitis Neurolysis Therapy™ (RNT). ...

ByNeurent Medical


AOBiome Achieves Landmark Recruitment Goal in Largest Clinical Trial Ever Powered by a Live Topical Biotherapeutic

AOBiome Achieves Landmark Recruitment Goal in Largest Clinical Trial Ever Powered by a Live Topical Biotherapeutic

Additionally, recently published immunology data demonstrates that B244 can reduce the inflammatory and pruritic cytokines IL-4, IL-5, IL-13, and IL-31. About AOBiome Therapeutics, Inc. AOBiome Therapeutics, Inc. is a Cambridge, MA-based life sciences company focused on transforming human health by developing topical biologic therapies for local, nasal and systemic ...

ByAOBiome Therapeutic, LLC


AB2 Bio expands Phase 3 trial of Tadekinig alfa in monogenic HLH

AB2 Bio expands Phase 3 trial of Tadekinig alfa in monogenic HLH

There are currently no drugs specifically approved to treat IL-18 driven monogenic HLH and severe inflammatory conditions; disability and death are common outcomes. Dr. Michael Soldan, CEO of AB2 Bio commented: “We are pleased to expand this Phase 3 trial of Tadekinig alfa to adults and thus offering participation in this trial to a wider patient ...

ByAB2 Bio Ltd.


AOBiome`s 30 Patient Study Using New Shelf-Stable Formulation of its Ammonia Oxidizing Bacteria (AOB) Shows Significant Reduction of Itch Levels in Both Pediatric and Adult Subjects who Suffer from Eczema

AOBiome`s 30 Patient Study Using New Shelf-Stable Formulation of its Ammonia Oxidizing Bacteria (AOB) Shows Significant Reduction of Itch Levels in Both Pediatric and Adult Subjects who Suffer from Eczema

(“AOBiome”), a leading clinical-stage microbiome company focusing on inflammatory conditions, has announced the completion of a cosmetic study investigating the safety and effects of its novel AOB formulation on subjects with mild to moderate eczema. ...

ByAOBiome Therapeutic, LLC


Nature Scientific Reports has published a peer reviewed paper showing important immune response benefits associated with AOBiome`s B244 Ammonia Oxidizing Bacteria drug therapy

Nature Scientific Reports has published a peer reviewed paper showing important immune response benefits associated with AOBiome`s B244 Ammonia Oxidizing Bacteria drug therapy

(“AOBiome”), a leading clinical-stage microbiome company focusing on inflammatory conditions, announced new findings indicating a link between Ammonia Oxidizing Bacteria (AOB) and the human immune system. ...

ByAOBiome Therapeutic, LLC


Imspex’s patent portfolio grows

Imspex’s patent portfolio grows

This is the platform that is used to screen for disease indications such as bacterial and viral respiratory tract infections, Group B Streptococcus infection, lung cancer and other chronic inflammatory respiratory conditions. We are pleased to be able to extend use of this technology from its roots in industrial and environmental applications to making a ...

ByImspex Diagnostics Ltd.


BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial

BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial

Atopic Dermatitis is characterised as a chronic relapsing inflammatory skin condition which manifests as itchy, inflamed skin. The addressable global patient population is estimated at 230 million. ...

ByBenevolent

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About XPRT Media

XPRT is a global industry marketplace and information resource. Online product catalogs, news, articles, events, publications & more.


  • FAQs
  • Company sitemap
  • Category sitemap
XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
Medical XPRT